Correvio Pharma Corp. Deferred Tax Assets, Valuation Allowance
Correvio Pharma Corp. had Deferred Tax Assets, Valuation Allowance of $38.99 million as of 2019-12-31, per its 20-F filed 2020-04-30.
Discontinued › Notes › Income Taxes › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsValuationAllowance · last filed 2020-04-30
- 2019-12-31: Deferred Tax Assets, Valuation Allowance $38.99M.
- 2018-12-31: Deferred Tax Assets, Valuation Allowance $27.40M.
- 2017-12-31: Deferred Tax Assets, Valuation Allowance $114.48M.
- 2016-12-31: Deferred Tax Assets, Valuation Allowance $112.86M.
| Period end | Deferred Tax Assets, Valuation Allowance | Deferred Tax Assets, Valuation Allowance as first filed |
|---|---|---|
| 2019-12-31 | $38.99M 20-F · filed 2020-04-30 | |
| 2018-12-31 | $27.40M 20-F · filed 2020-04-30 | |
| 2017-12-31 | $114.48M 40-F · filed 2019-03-13 | |
| 2016-12-31 | $112.86M 20-F · filed 2018-04-30 | |
| 2015-12-31 | $108.66M 40-F · filed 2017-03-29 | |
| 2014-12-31 | $103.73M 40-F · filed 2016-03-29 | |
| 2013-12-31 | $102.20M 40-F · filed 2015-03-27 | $87.80M 40-F · filed 2014-03-27 |
| 2012-12-31 | $77.89M 40-F/A · filed 2014-04-30 | |
| 2011-12-31 | $73.89M 20-F/A · filed 2013-04-18 |